Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 12OTHER 6NIH 3UNKNOWN 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Esophageal Neoplasms 8Breast Neoplasms 5Triple Negative Breast Neoplasms 3Stomach Neoplasms 1Recurrence 1Nasopharyngeal Neoplasms 1IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 1Pemetrexed 1Paclitaxel 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Adenocarcinoma × Paclitaxel × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡